Skip to main content

Improvement Seen in Some Features of PCOS With Weight Loss Interventions

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 5, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Nov. 4, 2024 -- Weight loss interventions are associated with improvement in some features of polycystic ovary syndrome (PCOS), according to a study published online Nov. 5 in the Annals of Internal Medicine.

Jadine Scragg, Ph.D., from the University of Oxford in the United Kingdom, and colleagues quantified the effect of weight loss interventions on clinical features of PCOS compared with usual care based on a review of randomized controlled trials. Twenty-nine comparisons with 1,529 participants were included in the primary analyses: 13, 12, and four comparisons were judged as high, some, or low risk for bias, respectively.

The researchers found that 12, nine, and eight of the comparisons used behavioral interventions, glucagon-like peptide-1 receptor agonists, and other weight loss medications, respectively. Significantly greater improvements in Homeostasis Model Assessment for Insulin Resistance, free androgen index, and menstrual frequency were seen in association with weight loss interventions (mean difference, −0.45, −2.03, and 2.64, respectively). No evidence was seen for weight loss interventions being associated with clinically or statistically significant improvements in hirsutism, quality of life, or other sex hormones.

"Clinicians may use these findings to counsel women with PCOS on the expected improvements in PCOS markers after weight loss and direct patients toward interventions, though our findings may not extend to all weight loss interventions especially if they target specific metabolic pathways," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted November 2024

Read this next

In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity

TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival...

GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression

MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...

Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery

THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.